SEHK:512Pharmaceuticals
How Positive Phase II Depression Trial Data For GPN01360 At Grand Pharmaceutical Group (SEHK:512) Has Changed Its Investment Story
Earlier this month, Grand Pharmaceutical Group announced that its innovative traditional Chinese medicine GPN01360 met the primary and multiple secondary endpoints in a randomized, double-blind, placebo-controlled Phase II depression trial in China, showing significant symptom improvement and favorable safety over eight weeks.
The result not only advances GPN01360 as a potential new option for depression with anxiety and insomnia, but also underlines Grand Pharmaceutical’s effort to extend...